
Heidelberg-based PromoCell has announced the launch of custom Good Manufacturing Practice (GMP) cell culture media services designed specifically for clinical applications and manufacturing within the cell-based therapy industry. This new initiative aims to address the rising demand for specialized cell culture media in regenerative medicine.
Introduction of Advanced Services
During the upcoming 32nd European Society of Gene and Cell Therapy (ESGCT) Congress in Seville, Spain, taking place from October 7 to 10, PromoCell will showcase its comprehensive GMP cell culture media service portfolio. According to CEO Irma Börcsök, the company is excited to introduce these services to the life science community, responding to a significant market need.
Börcsök stated, “We noticed an increasing demand for advanced cell culture media in regenerative medicine and cell-based therapy, and we are thrilled to introduce our GMP cell culture medium service portfolio.” This move reflects a commitment to enhancing the research-to-commercialization pathway for clients engaged in clinical applications.
Collaboration and Compliance
PromoCell emphasizes a collaborative approach in developing these services. Lucía Cespón, PhD, who leads the GMP business unit, highlighted the importance of client partnerships: “We’ve worked closely with our clients in clinical applications to ensure that both our custom GMP cell culture media services and our advanced cell culture media product portfolio, ‘PromoExQ,’ ensure the precision and compliance that modern translational research demands.”
The introduction of tailored GMP-grade media is essential for companies seeking to meet rigorous regulatory standards while advancing their research. The new offerings will provide essential support for organizations navigating the complex landscape of cell-based therapies.
PromoCell will be exhibiting at Booth A35 during the ESGCT Congress, where attendees can learn more about these innovative services and their implications for the future of cell therapy.